

# Reflection of OMS 2022

**Dr Pranzatelli**



**Dr Pistoia**



**Dr Wilson**



# SESSION 1 : Updates, Progress and Initiatives

- OMS Consensus statement
- OMS life registry
- POOMAS

# SESSION 2 : Trials, Studies and Interventions

- EU trial closed to recruitment
- COG trial neurodevelopmental outcome (functional)
- Moving forward with trials

# Immunobiology sessions

- Pathogenesis: B cell vs T cell debate (+cytokine/chemokines)
- Antigen and Antibody discovery efforts continue
- Gluk2 - new neuronal surface Ab target?
- Monoclonal Abs in other autoimmune disease '**-mabs**'
- HSCT in OMAS - more research needed

# Therapies

- Consensus statement – ‘game changer’
- Early treatment (higher efficacy) **vs** Escalation
- **Rituximab** discussion – and need for RCT...
- Using of newer ‘**-mabs**’ as per rheumatology

# Neuroimaging

- **Multimodal** imaging and correlation with pathobiology
- **Advanced** imaging techniques
  - PET in MS – straight to the target – OMAS parallel
  - 7T imaging – higher resolution but uniformity issues

# Neurobehavioral

- Long term effects – i.e. **beyond 5 years?**
- **Subtle** neurobehavioral changes
- Which cognitive tests to use?
- **Challenges with assessments** – lack of neuropsychologists and access to testing



# Future Directions

- Services: Transition to adults
- Antibody hunting continues
- Tissue bank and CSF/blood bank
- Multi-centre collaboration